Lipoprotein(a) and Apolipoprotein B: The Cholesterol Tests Your Annual Check-Up Might Be Missing
If you've had a health check in Japan — whether the standard company check-up or a more thorough "ningen dock" — you've probably seen your cholesterol numbers: total cholesterol, LDL-C (aka the "bad" cholesterol), HDL-C (aka the "good" cholesterol), and triglycerides. These numbers are useful, but they don't tell the whole story of your cardiovascular risk.
Two additional blood markers — Lipoprotein(a), or Lp(a), and Apolipoprotein B, or ApoB — can reveal risk that a standard lipid panel misses entirely. Both are now addressed specifically in cardiology guidelines in the United States and Europe. Neither is part of routine Japanese guidelines or standard health checks here.
Here's what each test measures, what an elevated result means, and how the guidelines differ between Japan and the West.
What is Lipoprotein(a)?
Lp(a) is a particle that looks a lot like LDL cholesterol, but with an extra protein — apolipoprotein(a) — attached to it. Think of it as a distinct, separate lipid particle that a standard cholesterol panel does not measure at all; it requires its own dedicated blood test.
Here's a simple way to picture it: if an LDL particle is a delivery truck carrying cholesterol cargo through your bloodstream, Lp(a) is that same truck with a grappling hook bolted onto the side. That hook makes it more likely to snag on the wall of an artery and contribute to plaque buildup. And unlike the cargo itself, you can't unbolt the hook through diet or exercise — it's a factory-installed feature, set by your genes.
A few things make Lp(a) unusual compared to other cholesterol markers:
It's largely inherited. Roughly 70-90% of your Lp(a) level is determined by genetics, set early in life. Diet, exercise, and weight loss — the usual levers for improving cholesterol — have very little effect on it.
It doesn't change much over time. Because Lp(a) is largely genetically determined and relatively stable, current guidelines generally recommend measuring it at least once in adulthood rather than testing it repeatedly.
The test itself is simple. It's a standard blood draw, and fasting isn't required.
What is Apolipoprotein B (ApoB)?
Every artery-clogging ("atherogenic") lipoprotein particle in your blood — LDL, VLDL, IDL, and Lp(a) — carries exactly one ApoB molecule on its surface. So while LDL-C tells you how much cholesterol is packed inside your LDL particles, ApoB tells you how many of those particles you actually have circulating.
That distinction matters because it's particle number, not cholesterol content, that drives plaque buildup in your arteries. Going back to the delivery truck picture: LDL-C measures the total weight of cargo being delivered, while ApoB counts the actual number of trucks on the road. Ten trucks each carrying a light load can cause just as much of a traffic pile-up (plaque) as five trucks each carrying double the cargo — the truck count matters as much as the cargo weight.
In most people the two numbers move together, but they can diverge — particularly in people with diabetes, metabolic syndrome, obesity, or high triglycerides. In these situations, LDL particles tend to become smaller and more cholesterol-depleted, so LDL-C can look reassuringly normal even though the actual number of atherogenic particles (and the true risk) is elevated. ApoB catches that discrepancy.
Like Lp(a), the ApoB test is a simple blood draw and can be added to a routine panel.
Putting the whole picture together, the delivery-truck metaphor looks like this:
Why elevated levels matter
Lp(a): Elevated Lp(a) is now recognized as an independent, largely genetic risk factor for atherosclerotic cardiovascular disease — heart attack, ischemic stroke, and peripheral artery disease — as well as for calcific aortic valve stenosis (narrowing of the heart's aortic valve). Roughly 1 in 5 people worldwide have an elevated level, often without any idea, since it isn't part of routine testing. A strong family history of early heart disease or stroke is a common clue that prompts a doctor to order this test.
As of today, there is no medication specifically approved to lower Lp(a) itself, though several are in late-stage clinical trials with cardiovascular outcome results expected over the next year or two. That doesn't make the test pointless in the meantime — quite the opposite. Knowing you carry an elevated Lp(a) reclassifies your overall cardiovascular risk and typically prompts more aggressive management of the risk factors that can be treated: LDL-C, blood pressure, and smoking, along with closer long-term monitoring.
ApoB: An elevated ApoB simply means you have more artery-clogging particles — more "trucks on the road" — circulating in your blood than is healthy, even if your standard cholesterol numbers look fine. This is especially useful to know if you have diabetes, high triglycerides, or extra weight around the middle, since these conditions can make LDL-C look deceptively normal while the actual particle count is high. Doctors are increasingly using ApoB not just to gauge initial risk, but to check whether cholesterol-lowering treatment, like a statin, is actually working.
Included in US and European guidelines — not yet in Japan's
This is where the story becomes especially relevant if you live in Japan:
Europe: The 2025 ESC/EAS focused update recommends considering Lp(a) measurement at least once in every adult's lifetime. It also recognizes elevated Lp(a) as a cardiovascular risk modifier, particularly when risk is otherwise borderline or intermediate.
United States: Guidance from the American Heart Association/American College of Cardiology and the National Lipid Association similarly supports Lp(a) testing at least once for most adults, and supports ApoB as a preferred or complementary marker in higher-risk patients.
Japan: The 2022 Japan Atherosclerosis Society (JAS) guidelines recognize both Lp(a) and ApoB as clinically relevant markers of atherosclerotic cardiovascular risk. However, they have not been incorporated into the standard lipid panel used for routine health examinations, and LDL-C, HDL-C, triglycerides, and non-HDL-C remain central to routine risk assessment and treatment decisions. JAS notes that ApoB can be useful for assessing residual risk, particularly when LDL-C has reached its treatment goal, while acknowledging that evidence is insufficient to replace LDL-C as the primary therapeutic target.
None of this means Japanese guidelines are "behind" — guideline bodies weigh evidence, cost-effectiveness, and healthcare system priorities differently, and JAS has its own robust, actively updated framework. But if you've been following US or European cardiology guidance, or you have a family history that concerns you, it's worth knowing that these two tests exist and simply aren't part of the standard workup here.
Should you get tested?
It's reasonable to consider Lp(a) and ApoB testing if any of the following apply to you:
You have a personal or family history of early heart attack, stroke, or heart disease (especially before age 55 in men or 60-65 in women, depending on the guideline)
You have high cholesterol that runs in your family, or a personal or family history that suggests familial hypercholesterolemia
You've had a cardiovascular event despite "normal" LDL-C
You have diabetes, metabolic syndrome, or high triglycerides, where LDL-C alone may understate your risk
You're already on a statin or other lipid-lowering therapy and want a fuller picture of your risk and treatment response
You simply want a more complete, proactive look at your cardiovascular risk
Testing available at Cedar Medical Clinic Tokyo
Both Lp(a) and ApoB testing are available at Cedar Medical Clinic Tokyo as an add-on to a standard blood panel — a simple blood draw with no special preparation needed. Results are reviewed and explained in person by a U.S.-trained, English-speaking doctor, so you can discuss what your numbers mean and how they fit into your overall cardiovascular risk in plain English.
To book an appointment or ask about adding these tests to your next blood panel:
Cedar Medical Clinic Tokyo
〒153-0062 MT Building 2nd Floor, 2-1-9 Mita, Meguro-ku, Tokyo
Phone: 03-6303-3113
Hours:
Mon, Tue, Wed, Fri 9:30–17:30;
1st & 3rd Saturday 9:00–12:30
(closed Thursdays, Sundays, and public holidays)
This article is intended for general educational purposes and isn't a substitute for personalized medical advice. Talk to your doctor about whether Lp(a) and ApoB testing make sense for your individual risk profile.
References
Mach, F. et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias.European Society of Cardiology / European Atherosclerosis Society, 2025. https://eas-society.org/publications/guidelines/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias/
European Society of Cardiology. Dyslipidaemias — Clinical Practice Guidelines.https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/dyslipidaemias/
Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle? Atherosclerosis, 2025. https://www.atherosclerosis-journal.com/article/S0021-9150(25)01385-1/fulltext
Dyslipidemia: ESC/EAS 2025 Guideline Expert Insight. Medscape. https://reference.medscape.com/cc1/p10/dyslipidemia-guideline-achieve-cholesterol-targets-2026a10003e6
Okamura, T., Tsukamoto, K., Arai, H., et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. Journal of Atherosclerosis and Thrombosis, 31(6), 641–853, 2024. https://doi.org/10.5551/jat.GL2022
Lipoprotein(a) in Japanese Patients With Cardiovascular Disease: A Systematic Review. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S2772374725004624
Amgen. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial. ClinicalTrials.gov, NCT05581303. https://clinicaltrials.gov/study/NCT05581303
Emerging Therapies for Lowering Lp(a): "Peering into the Future." Healio, 2025. https://www.healio.com/news/cardiology/20250811/emerging-therapies-for-lowering-lpa-peering-into-the-future
New Therapies on the Way to Lower Lp(a), a Cardiovascular Risk Factor. Managed Healthcare Executive, 2026. https://www.managedhealthcareexecutive.com/view/new-therapies-on-the-way-to-lower-lp-a-a-cardiovascular-risk-factor
Family Heart Foundation. Ongoing Clinical Trials Targeting Lipoprotein(a). https://familyheart.org/lpa-clinical-trials
Comments